# An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

> **NCT00127647** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 1375 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** montelukast sodium
- **DRUG:** Comparator: pranlukast

## Key facts

- **NCT ID:** NCT00127647
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 1375 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127647, "An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00127647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*